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Abstract
Purpose: Radiotherapy has been shown to be an effective for the treatment human glioma and consists of 30
fractions of 2 Gy each for 6-7 weeks in the tumor volume with margins. However. in preclinical studies, many
different radiation schedules are used. The main purpose of this work was to review the relevant literature and to
propose an external whole-brain irradiation (WBI) protocol for a rat 9L glioma model.
Materials and methods: 9L cells were implanted in the striatum of twenty 344-Fisher rats to induce a brain
tumor. On day 8, animals were randomized in two groups: an untreated group and an irradiated group with three
fractions of 6 Gy at day 8, 11 and 14. Survival and toxicity were assessed.
Results: Irradiated rats had significantly a longer survival (p = 0.01). No deaths occurred due to the treatment.
Toxicities of reduced weight and alopecia were increased during the radiation period but no serious morbidity or
mortality was observed. Moreover, abnormalities disappeared the week following the end of the therapeutic
schedule.
Conclusions: Delivering 18 Gy in 3 fractions of 6 Gy every 3 days, with mild anaesthesia, is safe, easy to reproduce
and allows for standardisation in preclinical studies of different treatment regimens glioma rat model.
Background
Malignant glioma is the most frequent primary brain
tumor. Prognosis is extremely poor with current stan-
dards of treatment. Median survival is less than fifteen
months with a multimodality treatment of surgery, radio-
therapy (RT) and chemotherapy [1]. Temozolomide, a
novel alkylating agent, has shown modest activity against
recurrent glioma. However, in newly diagnosed patients
with glioblastoma, temozolomide in combination with
radiotherapy significantly prolongs survival. Radiotherapy
represents a significant part of the treatment regimen for
malignant glioma [2-4]. To be sufficiently efficacious
with acceptable toxicity, RT consists of 30 fractions of 2
Gy each, usually administered Monday-Friday for 6-7
weeks (42 days) in the tumor volume with margins. The
schedule is clearly defined and established in clinical
practice [5]. Consequently, in preclinical studies evaluat-
ing adjuvant therapies, radiation therapy should be
included. Previously, we used a fractionated radiation
schedule delivering 36 Gy in 9f r a c t i o n so f4G yt ot r e a t
C6 tumor bearing-rats [6]. We found that brain radio-
therapy for rat 9L-glioma, which is the most common
preclinical model used, is not standardized. Moreover,
the schedules described in literature are highly heteroge-
neous (Table 1) [6-13]. To prove a potentially promising
effect of a concomitant treatment and to compare differ-
ent study results, the radiation therapy protocol must be
well defined. Following a review of the literature, the aim
of this study is to propose a brain irradiation protocol for
rats that is closer to clinical practice, safe for small ani-
mals and easy to reproduce in the study of concomitant
treatments for glioma.
Methods
All experiments have been conducted under good
experimental practices. All animal handling was carried
out according to the European Community regulations
and French Ministry of Agriculture regulations.
Animals
20 females Fischer-344 rats were used for this study
(Charles River, Cleon, France). Rats were ten weeks-old,
and weighed 150 to 200 grams. They were housed in
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directives of the European Union. Animal handling was
conducted by the animal facility of the Faculty of Medi-
cine of Angers, approved according to French law.
Tumor model
Rat 9L-glioma cells (European Collection of Concealment
Culture, n° 94110705, Salisbury, U.K.) were cultured in
“DMEM” medium ("Dulbecco’s Modified Eagle’sM e d -
ium”, Biowhittaker, Verviers, Belgium) with 10% foetal calf
serum (FBS, Biowhittaker) and a mixture of antibiotics:
penicillin (100 UI/ml), streptomycin (0.1 mg/ml) and
amphothericin B (25 μg/ml) (ABS, Sigma, Saint Quentin
Fallavier, France). Cells were maintained in a balanced wet
atmosphere (37°C and CO2 5%).
Animals were anesthetized with an intraperitoneal
injection of 0.75-1.5 ml/kg of a solution containing 2/3
ketamine (100 mg/ml) (Clorketam®, Vétoquinol, Lure,
France) and 1/3 xylazine (20 mg/ml) (Rompun®, Bayer,
Puteaux, France). Rats were placed in a small-animal
stereotaxic frame (Kopf Instruments, Phymep, France).
After shaving and disinfection of the skin, a sagittal inci-
sion of 2 cm was made to expose the skull, followed by
a burr hole 0.5 mm anterior and 3 mm lateral from the
bregma using a small drill.
Following trypsinisation (trypsin/EDTA (Sigma)) and
resuspension in “EMEM” ("Eagle’s Minimum Essential
Medium”, Biowhittaker), 10 μlo f1 0
3 9L-cells in suspen-
sion were implanted 5 mm deep in the right striatum
(according to the Paxinos atlas) using a 10 μl -26G
Hamilton syringe (Harvard Apparatus, Ulis, France).
After waiting 5 minutes, the needle was removed and
the wound was sutured with absorbable surgical thread.
Rats bearing 9L tumor were randomized to either the
“untreated” group (group A) or the group irradiated by
a whole-brain irradiation (WBI) to a total dose of 18 Gy
(group B). The radiotherapy started on day 8 after the
tumor cell implantation when the tumor size was 10-15
μl [14].
Radiotherapy protocol
Rats were irradiated using a 6-MV linear accelerator
(Saturn 41 type, Varian Medical Systems, Salt Lake City,
USA), under mild anaesthesia by isoflurane (4.5% during
2 minutes then 2% for the treatment) + O2 3L / m i n .
Oxygen masks were connected and four rats were
placed in a reproducible way, in a prone position on the
linac couch with laser alignment. The WBI was deliv-
ered by one photon beam (6 MV-energy, DSP 100 and
4 Gy/min). The radiation field was 15 × 15 cm at
source-axis distance of 100 cm. The isocenter was in the
midline of the brain and the posterior limit of the field
corresponded to the line passing by the posterior part of
the 2 ears (Figure 1).
A 15-mm thickness of equivalent tissue was laid on
the rat’s head in order to improve dose distribution to
the brain. The dose distribution was defined by the
Radiation Therapy department. Eighteen Gy, given in 3
fractions of 6 Gy were delivered over 7 days in the iso-
center corresponding to the tumor (Figure 2). The brain
was covered by the 95%-isodose. The irradiation was
only started in the absence of wound healing problems
(abscess, haematoma...) and if rat’s general state allowed
it. After irradiation, animals were replaced in their cage.
Control rats were also anesthetized according to the
same schedule as the group B animals.
Animal observation
Rats were examined daily and staged for activity and
well-being according to a classification developed in our
animal facility (data not published) (Table 2). Toxicities
were noted. Rats were weighed weekly. Rats too weak to
Table 1 Studies using radiation therapy rat model in combination with anticancer therapeutic agents
Studies Target Tumor Cell line Total dose Number of fractions Survival
Roullin VG (6) HB C6 36 Gy 9 Complete response : 8%
Graf MR (7) WB T9 15 Gy 1 35 days (median)
Kimler BF (8) WB 9L 20 Gy 1 S
30 Gy 5 S
Kimler BF (9) WB 9L 40-70 Gy 10-20 S
Kimler BF (10) WB 9L 16 Gy 1 38.5 days (mean)
Kimler BF (11) WB 9L 16 Gy 1 S
24 Gy 1 S
32 Gy 1 S
40 Gy 1 S
Lamproglou I (12) WB - 30 Gy 10 -
Olson JJ (13) WB 9L 30 Gy 1 29.7 days (mean)
WB: Whole brain/HB: Hemibrain/S: Significant
NB: Lamproglou worked on normal rat brains.
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ficed (atmosphere saturated with CO2). The day of
euthanasia was recorded and used in the survival analy-
sis. All brains were removed and macroscopically exam-
ined when possible. It was noted if a tumor was found.
Statistics
Survival was calculated from the day of the tumor
implantation and presented as median and mean ± SE
(Standard Error). Increase of life span (ILS) was calcu-
lated as follows: (Mean Survival Max - Mean Survival
Min)/Mean Survival Min × 100. A Student t-test was
performed to compare mean survival in the two groups,
using SPSS® software and tests were considered as sig-
nificant with p values < 0.05. Any rat surviving longer
than 120 days was defined as a ‘long survivor’.T h e
Kaplan-Meier method was used to plot animal survival.
Animals that died during anesthesia were not included
in the survival analysis.
Results
Efficacy of the brain irradiation
The dosimetry planning is reported in figure 3. The
95%-isodose curve covered all the brain and 95% of the
volume received 95% of the total dose. In the group A,
two animals died during anaesthesia induction, before
the tumor cells implantation. The brain was analyzed
macroscopically in 12 animals (six in group A and six in
group B). Deterioration of the brain in other animals,
due to oedema, prevented analysis. For the 12 animals, a
large tumor was observed in their right striatum. By day
35, all rats in group A died. Mean survival of this
untreated group was 28.1 days ± 1.3. For group B, mean
survival was 59.9 days ± 8.2 (Table 3). The rate of long
survivors in this group was 20% (2/10 rats). The macro-
scopic examination of their brain was normal, with no
sign of tumor or injection trail; therefore we did not
perform a microscopic analysis. Rats treated with WBI
showed an increased mean survival span (ILS) of 113%
when compared to controls. Survival time was signifi-
cantly longer compared to the control group (p = 0.01)
(Figure 4).
Schedule toxicity
No rat, in any group, developed evident behavioural
anomalies until approximately four days preceding
death. Rats of the 2 groups were either sacrificed at
stage 2 to avoid suffering or died spontaneously during
the night (n = 8). The others twelve rats were found
dead in the morning. There were no issues with wound
healing following the procedure. All rats in group B
developed incomplete and reversible (WHO grade II)
alopecia at the surgical site during radiation therapy.
Animals recovered by 21 days following the last day of
irradiation. During the radiation therapy (d8-d14), the
general behaviour was maintained, with no feeding trou-
ble although the weight increase was slower than
observed for rats in group A. For group A, weight gain
was typical for twelve week-old rats. The mean increase
in weight for the “untreated” group A was 7.69%
b e t w e e nd 8a n dd 2 0v e r s u s2 . 4 7 %f o rt h eW B Ig r o u p
(figure 5). This difference was significant (p = 0.01). In a
previous study (14), mean time of survival of the
Figure 1 Radiation therapy position. An equivalent tissue of 1.5
cm was laid on the rat head in order to improve the dose
distribution in brain.
Figure 2 Therapeutic schedule.
Table 2 Rats staging (data not published)
Stage 5 Stage 4 Stage 3 Stage 2 Stage 1
Motility Normal Normal + but not
spontaneous
Reduced No
Stature Normal Stooped
+
Stooped ++ Stooped
+++
Dying
Piloerection No +/- +++ +++ +++
Eyes sharp Redness
+
Redness ++ Eye
secretions
closed
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have been noted for a significant number of rats due to
neurological deterioration related to the tumor progres-
sion. So, for group A, values of the weight increase after
day 20 resulted from an extrapolation starting from the
weight increase noted during the first 14 days. Weight
gain was no longer significantly different one week after
the end of radiation therapy (day 21) (p = 0.25) with an
increase of weight estimated at 3.79% for group A and
6% for the group B (figure 5). No other clinical abnorm-
alities due to irradiation were observed.
Discussion
Even though single-fraction irradiation was reported to
be well tolerated in the literature, we decided to use a
fractionated radiotherapy protocol to irradiate rats, as
this is closer to clinical practice and more adapted for a
preclinical study, especially with daily concomitant che-
motherapy as defined by Stupp for human gliomas [1]. In
the literature, from 5 to 20 fractions have been delivered
in the preclinical studies we reviewed (Table 1) [[6,8,9]
and [12]]. One potential limitation of fractionated radio-
therapy for small animals is the reproducibility of
Table 3 Descriptive and statistical data from the survival study depending on groups of treatment
GROUPS Median of survival
(days)
Mean time of survival (days)
±S E
Mean ILS
(%)
Long term
survivors
Maximal time of survival
(days)
Group A « untreated » (n
=8 )
27 28.1 ± 1.3 - 0 35
Group B « WBI » (n = 10) 49.5 59.9 ± 8.2 113 2 120
WBI: Whole brain irradiation.
ILS: increase in lifetime span.
Figure 3 Dose distribution in the whole rat brain.
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Page 4 of 8positioning. In these small animal models, rats have to be
anesthetized, especially if one hemi-brain irradiation is
required. However, most drugs used for anaesthesia have
effects on blood brain pressure, which is already high
when a brain tumor grows, or are known to be radiopro-
tective for the normal brain parenchyma. Ketamine,
which is commonly used for anaesthesia of rodents,
induces a general increase in cerebral blood flow at
anaesthetic concentrations [15]. Some authors reported
that pentobarbital protects against radiation-induced
damage to normal rat brain. Even though there is no con-
c l u s i v ee v i d e n c ef o re i t h e rr a dioprotection or significant
improvement of radiotherapeutic efficacy, in 9L rat brain
tumor model pentobarbital could potentially induce the
selective protection of normal brain [11,13]. In our
model, anaesthesia with isoflurane is easy to use every
three days, is well tolerated by rats with a complete and
immediate recovery after irradiation and does not inter-
fere with normal or brain tumor cells.
Some investigators use Plexiglas stereotactic frames
for rat positioning and treat just one hemi-brain. Pre-
viously, in our laboratory, we used a fractionated radio-
therapy in one hemi-brain [6]. We found that the
volume of interest is better covered when the whole
brain is treated, as opposed to hemi-brain irradiation,
due to the small size of a rat brain (figure 6). The Dose
Volume histogram (DVH) obtained for these two treat-
ment modalities are represented in figure 7.
The optimal dose per fraction to treat a rat brain
glioma is not well defined. Our protocol was selected
based on the linear-quadratic formula with a/b of 10
for the tumor and a/b of 3 for the normal tissue. The
effective biological dose for the normal tissue is 32 Gy
and 27 Gy for the tumor. These doses correspond to
the dose received in clinical practice for a whole brain
irradiation. 9L cells are classified as a radioresistant cell
line especially compared to other rodent glioma cell
lines [16]. Bencokova described a surviving fraction at 2
Gy (SF2) of 71.9% for 9L cells against 53.0 and 41.4%
for C6 and F98 cell lines respectively [16]. According to
this, the dose to deliver by fraction must be higher than
2 Gy. The dose per fraction in literature ranges from 2
to 40 Gy (Table 1). For Kimler, the survival improve-
ment was limited by the development of normal tissue
toxicity at high doses [11]. Kim observed that 35 Gy
produced severe optic neuropathy [17]. In his study, he
t e s t e das i n g l eh i g hd o s eo fr a d i a t i o n( r a n g i n gf r o m2 0
to 45 Gy) with radiosurgery in a limited volume. Pre-
viously, we investigated a radiation therapy schema in 3
fractionated doses of 6 Gy a week in vitro on 9L cell
lines without and with concomitant chemotherapy [18].
Figure 4 Survival curves depending of each group of
treatment. Survival times (days) after tumor implantation have been
plotted for “untreated animals” (Group A) and “WBI (3 fractions of 6
Gy)” animals (group B).
Figure 5 Evolution of the weight median depending on time of observation according to the group.
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Page 5 of 8The results showed that cell death was most important
as the number of fractions increased from 1 to 3 and
the increase was higher for the schemas associated with
chemotherapy. For all the conditions tested, the greatest
cell death was obtained after the first fraction (60-75%
cell death), and was slightly reduced after the second
and the third fraction. On the other hand, the most
important observation was the synergistic effect between
chemotherapy (CT) and RT which was most evident
after the third fraction, as cell death increased from
5.3% to 38.2% for the cells treated with RT alone versus
CT + RT, respectively. After the third fraction, the cell
percentage still alive was mainly due to the radioresis-
tance mechanism described above. Taking these findings
into consideration, with the aim of finding a treatment
protocol that is efficacious but not toxic, we chose to
deliver 3 fractions of 6 Gy in our model of rat glioma.
With this schedule we noted a mild and transitory toxi-
city which was quickly reversible after treatment.
Two rats in the WBI group lived more than 120 days.
They were sacrificed and their brain was removed; there
was no sign of tumor. It is not possible to determine
whether there was a technical problem during the
tumor cells implantation or if the animals achieved a
complete response after irradiation.
There is a paucity of experimental data in literature
on rat radiobiology. Different energy sources are used.
Some groups work with a dedicated irradiator for small
animals in their laboratory. This type of irradiator uses
137Cesium or
60Cobalt source and delivers gamma-rays
[[9,19,20] and [21]]. As Lamproglou, even though his
work was on normal brain [12], we decided to treat our
rats with linear accelerator used in clinical practice. Ani-
mal irradiation may be difficult to manage because of
the limited availability of accelerators but the main
advantage is to deliver the same energy type as in clini-
cal practice. There are other advantages of using a non-
radioactive x-ray-producing irradiator such as avoiding
the increasing number of radioprotection controls as
well as the potential source hazard, disposal and repla-
cement; nonetheless the expected efficacy is the same
whatever the radiation source chosen.
Figure 6 Dose distribution in one hemibrain (A) and in the whole rat brain (B).
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optimal therapeutic regimen as it was conducted before
our studies into the efficacy of local chemotherapy con-
comitant to radiation therapy in 9L glioma [22].
Another study confirms the reproducibility of the model
as we obtained the same improvement in survival in the
radiation group compared to the untreated group [18].
Therefore, this radiation therapy protocol has the poten-
tial to induce strong tumor debulking and facilitate con-
comitant chemotherapy treatment.
Conclusion
Many models of radiation therapy for rat glioma are
available, with different schedules. We describe a repro-
ducible paradigm of fractionated radiotherapy for rat
bearing a brain tumor, which reflects clinical practice,
with a good compromise between feasibility and adapta-
tion to chemotherapy radiosensitization studies.
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